MDxHealth (NASDAQ:MDXH) Trading 0.5% Higher - Should You Buy?

MDxHealth SA (NASDAQ:MDXH - Get Free Report) rose 0.5% during trading on Monday . The company traded as high as $2.20 and last traded at $2.19. Approximately 57,635 shares were traded during trading, a decline of 36% from the average daily volume of 90,010 shares. The stock had previously closed at $2.18.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on MDXH shares. Wall Street Zen upgraded shares of MDxHealth to a "hold" rating in a report on Saturday, May 24th. Craig Hallum started coverage on shares of MDxHealth in a report on Thursday. They issued a "buy" rating and a $8.00 target price for the company.

MDxHealth Trading Up 7.0%

The business's fifty day moving average is $2.10 and its 200-day moving average is $1.88. The stock has a market capitalization of $114.91 million, a PE ratio of -2.11 and a beta of 1.31. The company has a quick ratio of 1.92, a current ratio of 2.00 and a debt-to-equity ratio of 13.81.

MDxHealth (NASDAQ:MDXH - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.06). MDxHealth had a negative net margin of 41.02% and a negative return on equity of 492.11%. The company had revenue of $24.29 million during the quarter, compared to analysts' expectations of $22.62 million. As a group, analysts anticipate that MDxHealth SA will post -1.15 EPS for the current fiscal year.

Institutional Investors Weigh In On MDxHealth

Institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC purchased a new stake in MDxHealth during the fourth quarter worth approximately $25,000. FAS Wealth Partners Inc. lifted its position in shares of MDxHealth by 49.6% during the fourth quarter. FAS Wealth Partners Inc. now owns 24,425 shares of the company's stock worth $58,000 after purchasing an additional 8,100 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of MDxHealth during the fourth quarter worth $63,000. Castleview Partners LLC acquired a new position in shares of MDxHealth during the first quarter worth $48,000. Finally, Delta Investment Management LLC acquired a new position in shares of MDxHealth during the fourth quarter worth $81,000.

MDxHealth Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.